Sargent Bickham Lagudis’s Outlook Therapeutics OTLK Stock Holding History

Sargent Bickham Lagudis’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-50	Closed	-$1K	–	1002
2021 Q4	$1K	Buy	+50	New	+$1.78K	﹤0.01%	926

Other funds holding OTLK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vista Finance Clayton, Missouri $179M AUM 18.59% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Sargent Bickham Lagudis's OTLK Position: Q1 2022 in Review

Sargent Bickham Lagudis sold out of Outlook Therapeutics (OTLK) in Q1 2022, closing a stake of 50 shares — an estimated $1K sold.

Sargent Bickham Lagudis first reported a position in OTLK in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 73 funds tracked by Wall St. Rank hold OTLK as of Q1 2022.

Sargent Bickham Lagudis reported no remaining Outlook Therapeutics position as of Q1 2022 after selling out during the quarter.
Sargent Bickham Lagudis sold 50 Outlook Therapeutics shares in Q1 2022, an estimated $1K.
Sargent Bickham Lagudis first reported a position in Outlook Therapeutics in Q4 2021 and held it in 1 quarter.
Sargent Bickham Lagudis's Outlook Therapeutics position peaked at $1K in Q4 2021.
73 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q1 2022, filed 27 Apr 2022.